Feature | May 16, 2013

St. Jude Medical Gains European Approval of PCI 3-D Vessel Reconstruction Technology

System provides real-time 360-degree panoramic view of the arteries in 3-D, integrated FFR

The Ilumien Optis can reconstruct 3-D images on vessels and stent placements using OCT technology.

May 16, 2013 — St. Jude Medical gained CE mark approval of its Ilumien Optis percutaneous coronary intervention (PCI) optimization system to better visualize stent planning and navigation. The system will be on display for the first time in Europe during EuroPCR.

The Ilumien Optis system provides enhancements to the Ilumien system, including first-of-its-kind stent planning software tools to aid in the treatment of coronary artery disease (CAD). The Ilumien platform integrates both fractional flow reserve (FFR) technology to measure pressure inside the coronary arteries and intravascular optical coherence tomography (OCT) imaging technology, in one system.

Featuring a faster, high-powered laser, the Ilumien Optis system offers twice the resolution for microscopic examination of disease inside the artery to assist with stent placement. The real-time, 3-D reconstruction offers a 360-degree panoramic view of the vessel, making it easier for physicians to visualize the area they are treating. St. Jude Medical is the only company to provide these tools together in an integrated platform.

“OCT technology has become increasingly important to help diagnose and treat patients with coronary artery disease. The Ilumien Optis system is a significant advancement in intravascular imaging technology allowing physicians to comprehensively assess more vessel in less time and more easily plan their PCI procedure. The three-dimensional format of the Ilumien Optis system provides a more true-to-life perspective of the arteries, which allows for individual decision making and precise guidance of stent placement to optimize coronary interventions, said Dr. Giulio Guagliumi, cardiovascular department of Ospedale Papa Giovanni XXIII, Bergamo, Italy.

The OCT technology in the new Ilumien Optis system uses the Dragonfly Duo Imaging Catheter to capture near-infrared light imaging and measure important vessel characteristics otherwise invisible or difficult to assess with older imaging technology. When used with the system, the Dragonfly Duo catheter offers faster, longer pull-backs, which allow the physician to assess more of the patient’s artery in less time.

The wireless PressureWire Aeris technology that is integrated into the platform measures pressure differences in blood flow within the coronary arteries leading to the heart, and determines the severity of any narrowings or blockages. The FFR pressure guidewire is directed along the vessel, taking measurements as the guidewire is pulled back through the artery. Knowing which specific blockages are causing the patient’s blood flow to be ineffective helps guide the interventional cardiologist in determining which lesions warrant stenting, resulting in improved patient outcomes and reduced health care costs.

The FFR and OCT measurements captured by the Ilumien Optis system allow physicians to more easily differentiate plaque build-up and determine if the narrowed arteries are causing ischemia, ultimately assisting in stent placement. The automated stent planning tools provide immediate information for assessment and real-time analysis, which is intended to streamline workflow, potentially helping physicians diagnose their patients more quickly.

For more information: sjm.com

 

Related Content

HeartFlow, FFR-CT, ruptured coronary plaques, EMERALD study, EuroPCR 2016
News | CT Angiography (CTA)| May 23, 2016
First-in-human data presented at EuroPCR 2016 demonstrate that hemodynamic data from HeartFlow Inc. may help predict...
PCI, OFDI, OCT, optical coherence tomography, optimal frequency domain imaging, EuroPCR 2016 study
News | Intravascular Imaging| May 20, 2016
Using optimal frequency domain imaging (OFDI) to guide percutaneous coronary intervention (PCI) with second-generation...
Watchman, left atrial appendage closure, LAA occluder, LAA. LAAO, laa occluder, left atrial appendage, Watchman

The Boston Scientific Watchman device is currently the only transcatheter LAA occluder cleared for use in the United States.

Feature | Left Atrial Appendage (LAA) Occluders| May 20, 2016 | Dave Fornell
Atrial fibrillation (AF) affects nearly 6 million Americans and the condition puts them at significantly greater risk
St. Jude Medical, EuroPCR 2016 studies, FFR, LAAO, left atrial appendage occlusion, fractional flow reserve, Amplatzer
News | Cath Lab| May 19, 2016
St. Jude Medical Inc. announced results from two cardiovascular clinical trials presented at EuroPCR 2016.
clot, coronary thrombus, antiplatelet therapt, DAPT

An intravascular ultrasound (IVUS) image of a thrombus formed in a coronary artery.  While there are guidelines for antiplatelet therapy, there are still questions over the duration of such therapy. 

Feature | Antiplatelet and Anticoagulation Therapies| May 19, 2016 | Marianne Pop, Pharm.D., BCPS
There are many opinions on the duration of dual antiplatelet therapy (DAPT), highlighted at the 2016 American College
bioabsorbable vascular graft, children, feasibility study, Bakoulev Center Moscow, AATS 2016 meeting

Image courtesy of Bakoulev Scientific Center for Cardiovascular Surgery

News | Stent Grafts| May 18, 2016
Bioabsorbable heart valves or blood vessels are designed to harness the body’s innate healing process, enabling the...
NeoChord, DS1000 System, FDA approval, U.S. pivotal trial
News | Heart Valve Technology| May 17, 2016
NeoChord Inc. announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug...
Biotronik, Magmaris bioresorbable magnesium scaffold, BIOSOLVE-II Trial, 12-month results, EuroPCR 2016
News | Stents Bioresorbable| May 17, 2016
Biotronik presented 12-month data from the BIOSOLVE-II trial during a Hotline Session at EuroPCR 2016.

A Medtronic CoreValve TAVR device being deployed under angiographic image guidance.

 

Feature | Heart Valve Technology| May 16, 2016
 

Biosensors' Biomatrix stent.

Feature | Stents| May 16, 2016
May 16, 2016 — Cardinal Health announced it has entered into a distribution agreement with Biosensors that enables Co
Overlay Init